updat model capit rais pre-
publish updat model account preliminari result
capit rais last week pre-announc impress rev
beat impli core growth follow reflect
surg demand uniqu product also broader inflect across entir
bio-process space pf basi capit rais stock impli ev
rev maintain hold pt
beat pre-announc result last week point rev
beat ep beat impli strong
organ growth vs prior acceler
offer much color specif driver momentum across portfolio
clearli continu recal order grew overal note includ one-
month contribut recent c-tech acquisit close
bioprocess ecosystem fire eu-bas industri bellweth sartoriu also
report robust result bioprocess solut segment last week
annual rev bigger grew organ
core order grew acceler two-yr stack reflect broad-
base double-digit momentum across geographi includ project-rel
busi asia lift order sartoriu also rais bp core revenue growth
outlook mid-pt similarli pll life scienc grew dd
second straight period driven robust demand single-us technolog
new icelli single-us fixed-b bioreactor expect similarli posit data point
upcom updat other bioprocess ecosystem includ
week ge merck kgaa
capit rais detail also rais share dilut new
equiti new convert note offer due portion
use retir exist convert due
pro-forma basi figur cash exit provid
ampl liquid fund add futur exactli need cash
doubt anoth acquisit like next year follow recent c-tech deal
view move prudent step strengthen balanc sheet provid extra dri
powder given ytd stock action ytd
hike forecast maintain hold valuat expect report formal
result issu revis guidanc week rais revenu
forecast impli core growth assum
core growth tougher comp vs ep forecast
move continu think fundament pictur
never look brighter reluct chase valuat unchart
territori rev ebitda ep pt ev/rev
prem average
adjust exclud intang amort start
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
adjust exclud intang amort start
nopat compound-annual-growth-rate next decad
ep accret
ep accret
price impli ev rev
ep power assum accret bolt-
 deal/yr expand tam
price impli ev rev
delay launch advers clinic data new late-
price impli ev revenu
pure-play bioprocess consum
manufactur remain public arena
directli leverag secular growth biolog drug
see signific catalyst burgeon late-stag
biotherapeut pipelin
enabl sustain superior organ revenu growth
trajectori intermedi term
bolt-on acquisit activ expand tam
revenu synergi spectrum technoogi
faster ramp new product
pleas see import disclosur inform page report
pleas see import disclosur inform page report
corp histor project summari valuat analysisdollar million except per share amountshistor earn per flow cash cash flow ev cash flow per cash net interest free cash stock-bas sheet metricsreceiv day day day convers debt ttm debt ttm valu per cash per revenu jefferi llc estim project equiti research
pleas see import disclosur inform page report
corp histor project statement incomedollar million except per share amountshistor net product incom expens share share analysiscorpor gross margin analysisnet incom jefferi llc equiti research
corpor life scienc compani focus develop product commerci high-valu
consum product use process manufactur biolog drug
pt repres horizon dcf impli ev rev prem average risk new mab approv
 integr competit larger peer
brandon couillard certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
matthew stanton certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
